Moment of truth looms for Nektar, Bristol-Myers with a major update to NKTR-214 combo — and the latest snapshot is not promising
Just 8 months after Bristol-Myers paid Nektar $1.85 billion in cash upfront to ally themselves on NKTR-214, an IL-2 drug that uses pegylation tech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
